We are live on ! Find out more
FTH icon

Faeth Therapeutics
FTH

39 hedge funds and large institutions have $7.06M invested in Faeth Therapeutics in 2022 Q2 according to their latest regulatory filings, with 10 funds opening new positions, 7 increasing their positions, 16 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

1.43% less ownership

Funds ownership: 11.58% → 10.15% (-1.4%)

7% less funds holding

Funds holding: 42 → 39 (-3)

17% less first-time investments, than exits

New positions opened: 10 | Existing positions closed: 12

23% less capital inflows, than outflows

Capital inflows: $3.01M | Capital outflows: $3.93M

56% less repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 16

Holders
39
Holders Change
-3
Holders Change %
-7.14%
% of All Funds
0.65%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
10
Increased
7
Reduced
16
Closed
12
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
RA Capital Management
RA Capital Management
Massachusetts
+$1.36M
2
NM
Newtyn Management
New York
+$778K
3
Renaissance Technologies
Renaissance Technologies
New York
+$307K
4
E
Ergoteles
New York
+$175K
5
Millennium Management
Millennium Management
New York
+$157K

Top Sellers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
-$1.85M
2
State Street
State Street
Massachusetts
-$374K
3
Geode Capital Management
Geode Capital Management
Massachusetts
-$307K
4
JP Morgan Chase
JP Morgan Chase
New York
-$291K
5
Northern Trust
Northern Trust
Illinois
-$260K

FTH Hedge Fund Activity: Q2 2022 in Review

39 of the 5,963 institutional investors tracked by Wall St. Rank reported a position in Faeth Therapeutics (FTH) for Q2 2022, worth a combined $7.06M — down 14% from $8.21M a quarter earlier.

Sellers outnumbered buyers: 12 funds closed out of FTH and 10 opened new positions — a net loss of 2 holders — while 16 trimmed existing stakes and 7 added.

The largest buyer was RA Capital Management, opening a new position worth an estimated $1.36M. The largest seller was BlackRock, cutting an estimated $1.85M.

  • 39 institutional investors held Faeth Therapeutics (FTH) as of Q2 2022, down from 42 in Q1 2022.
  • Funds reported $7.06M of Faeth Therapeutics stock for Q2 2022, down 14% quarter-over-quarter.
  • 10 funds opened new Faeth Therapeutics positions in Q2 2022 and 12 closed out, a net change of -2 holders.
  • The largest Faeth Therapeutics buyer in Q2 2022 was RA Capital Management, an estimated $1.36M added.
  • The largest Faeth Therapeutics seller in Q2 2022 was BlackRock, an estimated $1.85M sold.

Based on aggregated 13F filings for Q2 2022.